Ken Griffin Immunocore Holdings PLC Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$30.06 - $41.49 $168,336 - $232,344	-5,600 Reduced 17.02%	27,300 $849,000
Q2 2024 Aug 14, 2024	SELL	$33.78 - $63.75 $560,748 - $1.06 Million	-16,600 Reduced 33.54%	32,900 $1.11 Million
Q1 2024 May 15, 2024	BUY	$60.14 - $75.36 $1.89 Million - $2.37 Million	31,500 Added 175.0%	49,500 $3.22 Million
Q4 2023 Feb 14, 2024	SELL	$42.85 - $69.5 $441,355 - $715,850	-10,300 Reduced 36.4%	18,000 $1.23 Million
Q3 2023 Nov 14, 2023	BUY	$49.5 - $66.6 $658,350 - $885,779	13,300 Added 88.67%	28,300 $1.47 Million
Q2 2023 Aug 14, 2023	SELL	$48.54 - $61.64 $106,788 - $135,608	-2,200 Reduced 12.79%	15,000 $899,000
Q1 2023 May 15, 2023	BUY	$46.12 - $65.71 $276,720 - $394,259	6,000 Added 53.57%	17,200 $850,000
Q4 2022 Feb 14, 2023	BUY	$45.51 - $65.08 $282,162 - $403,496	6,200 Added 124.0%	11,200 $639,000
Q3 2022 Nov 14, 2022	SELL	$37.34 - $57.44 $85,882 - $132,112	-2,300 Reduced 31.51%	5,000 $235,000

141

41.4M

197K

451K

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.29B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.